K Number
K252010
Device Name
SPY Laparoscope
Manufacturer
Date Cleared
2025-07-24

(27 days)

Product Code
Regulation Number
876.1500
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The SPY Laparoscope is intended to be used for gynecological and general procedures that clinicians deem appropriate for the adult or pediatric patient aged one month or older, when the dimensions of the SPY Laparoscope are appropriate for the patient size and anatomy.

Device Description

The SPY Laparoscope is part of Stryker's rigid endoscope product portfolio. The SPY Laparoscope is an optical instrument used to visualize or image a patient's anatomy during minimally invasive, endoscopic procedures for examination, diagnosis or therapy. The SPY Laparoscope transmits light in both the visible and near-infrared spectrum to illuminate the anatomy, then forms and relays the image of the surgical site to a camera system for image processing and display.

AI/ML Overview

The provided FDA 510(k) clearance letter for the SPY Laparoscope primarily details bench testing and compliance with various recognized standards to demonstrate substantial equivalence to a predicate device. It explicitly states that "The subject device does not require clinical studies to support the determination of substantial equivalence."

Therefore, the information you've requested regarding acceptance criteria and study proving performance, particularly related to human-in-the-loop performance, multi-reader multi-case studies, and the specifics of clinical ground truth establishment, is not available in this document. The clearance is based on a demonstration of equivalent technical performance and safety through non-clinical testing.

Here's how we can address your request based on the provided text, focusing on the available information:


Acceptance Criteria and Device Performance (Based on Non-Clinical Testing)

Since no clinical study data is presented, the "acceptance criteria" here refers to meeting the performance specifications and standards compared to the predicate device, primarily through bench testing.

1. Table of Acceptance Criteria and Reported Device Performance (Non-Clinical)

Acceptance Criteria CategoryReported Device Performance (Summary from Submission)
PackagingConforms to ASTM D4169:2022 (FDA-recognized standard)
Optical VerificationEquivalent to reference device for: Fiber Transmission, Illumination, Optical Transmission, Vignetting, Modulated Transfer Function (MTF), Distortion, Chromatic Aberration, NIR Transmission, Field of View (FOV), Apparent Field of View (AFOV), Image Runout. Conforms to ISO 8600-1:2015, ISO 8600-3:2019, ISO 8600-4:2023, ISO 8600-5:2020 (FDA-recognized standards).
Electrical SafetyConforms to IEC 60601-1:2020, IEC 60601-2-18:2009 (FDA-recognized standards).
BiocompatibilityConforms to ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-10:2021, ISO 10993-11:2017, ISO 10993-23:2021 (FDA-recognized standards).
Cleaning, Disinfection & Sterilization (Reprocessing)Conforms to AAMI TIR12:2020/(R)2023, ANSI AAMI ST98:2022, ANSI AAMI ST79:2017 + A1:2020, A2:2020, A3:2020, A4:2020, ANSI AAMI ST58:2024, ISO 17664-1:2021, ISO 17665:2024, ISO 14937:2009, ISO 22441:2022, ISO 15883-1:2006 + A1:2014, ISO 15883-2:2006, ISO 15883-5:2021 (FDA-recognized standards).
Risk ManagementConcluded that benefits outweigh residual risk; overall residual risk is acceptable. Conforms to ISO 14971 (FDA-recognized standard).

Information Not Available (Due to Reliance on Non-Clinical Testing)

The following points cannot be addressed from the provided document because the 510(k) clearance was based on non-clinical testing for substantial equivalence, not on clinical performance studies involving human subjects or AI:

2. Sample size used for the test set and the data provenance: Not applicable in the context of clinical data. The "test set" here refers to the physical units of the SPY Laparoscope and reference devices used in the various bench tests. Data provenance is internal lab testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. Ground truth for bench testing is derived from metrology and engineering standards.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This device is an endoscope, not an AI-driven image analysis tool. The document explicitly states "The subject device does not require clinical studies to support the determination of substantial equivalence."
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. This is a hardware device; no AI algorithm is mentioned or evaluated in this context.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc): For non-clinical tests, "ground truth" is defined by established engineering and optical standards, and measurements. For example, FOV measurements are compared against an acceptable range, not a clinical diagnosis.
8. The sample size for the training set: Not applicable. This is not an AI or machine learning device requiring a training set.
9. How the ground truth for the training set was established: Not applicable.


In summary: The FDA clearance for the SPY Laparoscope, as described in this 510(k) summary, is based entirely on a demonstration of non-clinical substantial equivalence to a predicate device. This includes demonstrating equivalent optical performance, electrical safety, biocompatibility, reprocessing efficacy, and overall risk management. Clinical studies or studies involving human-in-the-loop performance, AI, or advanced diagnostic accuracy metrics were not part of this clearance process.

FDA 510(k) Clearance Letter - SPY Laparoscope

Page 1

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

Doc ID # 04017.08.00

July 24, 2025

Stryker Endoscopy
Michelle Ross
Staff Specialist, Regulatory Affairs
5900 Optical Court
San Jose, California 95138

Re: K252010
Trade/Device Name: SPY Laparoscope
Regulation Number: 21 CFR 876.1500
Regulation Name: Endoscope And Accessories
Regulatory Class: Class II
Product Code: GCJ
Dated: June 27, 2025
Received: June 27, 2025

Dear Michelle Ross:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

Page 2

K252010 - Michelle Ross Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Page 3

K252010 - Michelle Ross Page 3

Sincerely,

JAMES H. JANG -S
Digitally signed by JAMES H. JANG -S
Date: 2025.07.24 07:23:06 -04'00'

James Jang, Ph.D.
Acting Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Page 4

Indications for Use

Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. K252010

Please provide the device trade name(s). SPY Laparoscope

Please provide your Indications for Use below.

The SPY Laparoscope is intended to be used for gynecological and general procedures that clinicians deem appropriate for the adult or pediatric patient aged one month or older, when the dimensions of the SPY Laparoscope are appropriate for the patient size and anatomy.

Please select the types of uses (select one or both, as applicable).

  • ☑ Prescription Use (Part 21 CFR 801 Subpart D)
  • ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

SPY Laparoscope Page 10 of 27

Page 5

510(k) Summary

510(k)#: K252010
Prepared on: 2025-07-23

Contact Details

21 CFR 807.92(a)(1)

FieldValue
Applicant NameStryker Endoscopy
Applicant Address5900 Optical Court San Jose CA 95138 United States
Applicant Contact Telephone408-677-6491
Applicant ContactMs. Michelle Ross
Applicant Contact Emailmichelle.ross1@stryker.com

Device Name

21 CFR 807.92(a)(2)

FieldValue
Device Trade NameSPY Laparoscope
Common NameEndoscope and accessories
Classification NameLaparoscope, General & Plastic Surgery
Regulation Number876.1500
Product Code(s)GCJ

Legally Marketed Predicate Devices

21 CFR 807.92(a)(3)

Predicate #Predicate Trade Name (Primary Predicate is listed first)Product Code
K221217SPY LaparoscopeGCJ
K910132Stryker LaparoscopeGCJ

Device Description Summary

21 CFR 807.92(a)(4)

The SPY Laparoscope is part of Stryker's rigid endoscope product portfolio. The SPY Laparoscope is an optical instrument used to visualize or image a patient's anatomy during minimally invasive, endoscopic procedures for examination, diagnosis or therapy. The SPY Laparoscope transmits light in both the visible and near-infrared spectrum to illuminate the anatomy, then forms and relays the image of the surgical site to a camera system for image processing and display.

Intended Use/Indications for Use

21 CFR 807.92(a)(5)

The SPY Laparoscope is intended to be used for gynecological and general procedures that clinicians deem appropriate for the adult or pediatric patient aged one month or older, when the dimensions of the SPY Laparoscope are appropriate for the patient size and anatomy.

Indications for Use Comparison

21 CFR 807.92(a)(5)

The subject device has the same indications for use and intended use as the predicate device.

Technological Comparison

21 CFR 807.92(a)(6)

Differences in technological characteristics, specifically a) smaller outer diameter (3.3mm vs. 5.4mm and 10mm), b) shorter working length (25cm vs. 30cm, 33cm and 45cm), and c) larger field of view (80°±5° vs. 75°±5°), do not raise different questions of safety or

Page 6

K252010

effectiveness. Testing summarized within this submission demonstrates the device conforms with design input requirements, user needs and intended uses. Comparative bench top testing demonstrates the subject and reference device's optical performance are equivalent. Risk management activities concluded that the benefits associated with the use of the device outweigh the residual risk. The overall residual risk is acceptable. The combination of this data demonstrates that the subject device is substantially equivalent with respect to safety and effectiveness to the legally marketed predicate device.

Non-Clinical and/or Clinical Tests Summary & Conclusions

21 CFR 807.92(b)

Non-clinical testing was designed and developed in accordance with applicable requirements and standards to establish performance and safety of the subject device (SPY Laparoscope). The following performance data were provided in support of the substantial equivalence determination:

1. Packaging

  • In accordance with FDA-recognized voluntary consensus standard ASTM D4169:2022 (14-576)

2. Performance – Bench

Comparative testing to currently legally marketed reference device:

  • Optical verification: Fiber Transmission, Illumination, Optical Transmission, Vignetting, Modulated Transfer Function (MTF), Distortion, Chromatic Aberration, NIR Transmission, Field of View (FOV), Apparent Field of View (AFOV), and Image Runout etc.
  • In accordance with FDA-recognized voluntary consensus standard ISO 8600-1:2015 (9-110)
  • In accordance with FDA-recognized voluntary consensus standard ISO 8600-3:2019 (9-123)
  • In accordance with FDA-recognized voluntary consensus standard ISO 8600-4:2023 (9-146)
  • In accordance with FDA-recognized voluntary consensus standard ISO 8600-5:2020 (9-131)

3. Electrical Safety

  • In accordance with FDA-recognized voluntary consensus standard IEC 60601-1:2020 (19-49)
  • In accordance with FDA-recognized voluntary consensus standard IEC 60601-2-18:2009 (9-114)

4. Biocompatibility

  • In accordance with FDA-recognized voluntary consensus standard ISO 10993-1:2018 (2-258)
  • In accordance with FDA-recognized voluntary consensus standard ISO 10993-5:2009 (2-245)
  • In accordance with FDA-recognized voluntary consensus standard ISO 10993-10:2021 (2-296)
  • In accordance with FDA-recognized voluntary consensus standard ISO 10993-11:2017 (2-255)
  • In accordance with FDA-recognized voluntary consensus standard ISO 10993-23:2021 (2-291)

5. Cleaning, Disinfection & Sterilization (Reprocessing)

  • In accordance with FDA-recognized voluntary consensus standard AAMI TIR12:2020/(R)2023 (14-602)
  • In accordance with FDA-recognized voluntary consensus standard ANSI AAMI ST98:2022 (14-583)
  • In accordance with FDA-recognized voluntary consensus standard ANSI AAMI ST79:2017 + A1:2020, A2:2020, A3:2020, A4:2020 (14-562)
  • In accordance with FDA-recognized voluntary consensus standard ANSI AAMI ST58:2024 (14-607)
  • In accordance with FDA-recognized voluntary consensus standard ISO 17664-1:2021 (14-578)
  • In accordance with FDA-recognized voluntary consensus standard ISO 17665:2024 (14-601)
  • In accordance with FDA-recognized voluntary consensus standard ISO 14937:2009 (14-337)
  • In accordance with FDA-recognized voluntary consensus standard ISO 22441:2022 (14-586)
  • In accordance with ISO 15883-1:2006 + A1:2014
  • In accordance with ISO 15883-2:2006
  • In accordance with ISO 15883-5:2021

6. Miscellaneous

  • In accordance with FDA-recognized voluntary consensus standard ISO 14971 (5-125)

Verification and validation testing successfully completed demonstrated that the device conform with recognized safety standards, design input specifications, user needs and intended uses.

The subject device does not require clinical studies to support the determination of substantial equivalence.

The SPY Laparoscope has the same intended use and indications for use, and fundamental technology as the predicate device. In summary, the SPY Laparoscope is the same or similar with respect to safety and effectiveness to the legally marketed predicate device.

§ 876.1500 Endoscope and accessories.

(a)
Identification. An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification —(1)Class II (special controls). The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.